Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 1 sale; 154 institutions reported holding it in 13F filings for Q2 2026, worth $314.4M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $1.49M in total
- 2
- Insider sellsLast 90 days, $65.7K in total
- 1
- 13F holdersQ2 2026, −14 vs. previous quarter
- 154
- 13F valueReported value at the end of Q2 2026
- $314.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding FULC, Q2 2026
No superinvestor reported holding FULC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Fulcrum Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)9:10 PM ET | Jul 16-17 | 4 days | Tang Kevin C and 1 other10% Owner | PPurchase | +167.6K | $3.55 | +$594.7K | +2.4%7.08M after | 2 lots |
| Jul 15, 2026 (view filing)7:50 PM ET | Jul 13-15 | 2 days | Tang Kevin C and 1 other10% Owner | PPurchase | +249.9K | $3.57 | +$891.1K | +3.8%6.91M after | 4 lots |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Ezekowitz AlanDirector | SSale | −18.0K | $3.65 | −$65.7K | −62.2%10.9K after | |
| Feb 4, 2026 (view filing) | Jan 2 | 33 days | Gould Robert JDirector | SSale | −15.0K | $10.87 | −$163.1K | −3.1%469.9K after | Amended |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Gould Robert JDirector | SSale | −15.0K | $10.72 | −$160.8K | −3.2%454.9K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Oltmans Curtis GaleChief Legal Officer | SSale | −3.45K | $12.92 | −$44.6K | −25.2%10.3K after | |
| Dec 10, 2025 (view filing)4:42 PM ET | Dec 8 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −4.18M | $13.98 | −$58.4M | −40.8%6.05M after | 3 lots |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Gould Robert JDirector | SSale | −15.0K | $11.03 | −$165.4K | −3.0%484.9K after | |
| May 9, 2025 (view filing) | May 8 | 1 day | Tourangeau GregPrincipal Accounting Officer | SSale | −498 | $5.06 | −$2.52K | −3.4%14.1K after | |
| May 9, 2024 (view filing) | May 7 | 2 days | Tourangeau GregPrincipal Accounting Officer | SSale | −236 | $7.76 | −$1.83K | −2.0%11.6K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Fulcrum Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 10,950,080 | $40.1M | 1.21% | +7,900,040+259.0% | Added |
| BlackRock, Inc. | 8,824,259 | $32.3M | 0.00% | +3,433,666+63.7% | Added |
| EcoR1 Capital, LLC | 6,549,866 | $24.0M | 1.19% | +6,549,866 | New |
| Tang Capital Management LLC | 6,521,412 | $23.9M | 1.08% | +6,521,412 | New |
| Suvretta Capital Management, LLC | 3,680,921 | $13.5M | 0.28% | −2,880,190−43.9% | Reduced |
| D. E. Shaw & Co., Inc. | 3,044,385 | $11.1M | 0.01% | +1,421,104+87.5% | Added |
| Citadel Advisors LLC | 2,704,505 | $9.90M | 0.01% | +1,412,019+109.2% | Added |
| Vanguard Capital Management LLC | 2,697,216 | $9.87M | 0.00% | +4,268+0.2% | Added |
| Jane Street Group, LLC | 2,217,498 | $8.12M | 0.01% | +1,907,081+614.4% | Added |
| State Street Corp | 2,037,025 | $7.46M | 0.00% | +487,174+31.4% | Added |